U01CA164947
Cooperative Agreement
Overview
Grant Description
Post GWA studies in testicular germ cell tumors.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Philadelphia,
Pennsylvania
19104
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/16 to 08/31/25 and the total obligations have increased 887% from $1,188,917 to $11,729,725.
Trustees Of The University Of Pennsylvania was awarded
Post genome wide association studies in testicular germ cell tumors
Cooperative Agreement U01CA164947
worth $11,729,725
from National Cancer Institute in September 2012 with work to be completed primarily in Philadelphia Pennsylvania United States.
The grant
has a duration of 13 years and
was awarded through assistance program 93.393 Cancer Cause and Prevention Research.
The Cooperative Agreement was awarded through grant opportunity Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 9/20/24
Period of Performance
9/21/12
Start Date
8/31/25
End Date
Funding Split
$11.7M
Federal Obligation
$0.0
Non-Federal Obligation
$11.7M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U01CA164947
Transaction History
Modifications to U01CA164947
Additional Detail
Award ID FAIN
U01CA164947
SAI Number
U01CA164947-2191119152
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
GM1XX56LEP58
Awardee CAGE
7G665
Performance District
PA-03
Senators
Robert Casey
John Fetterman
John Fetterman
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $3,664,842 | 100% |
Modified: 9/20/24